Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biased random walk model for the prioritization of drug resistance associated proteins

3 Jun 2015

Abstract excerpt

Multi-drug resistance is the main cause of treatment failure in cancer patients. How to identify molecules underlying drug resistance from multi-omics data remains a great challenge. Here, we introduce a data biased strategy, ProteinRank, to prioritize drug-resistance associated proteins in cancer cells. First, we identified differentially expressed proteins in Adriamycin and Vincristine resistant gastric cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bioinformatics and Genomic Networks
Share to Cancer Mechanisms and Therapy
Share to Computational Drug Discovery Methods

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26039373
DOI: 10.1038/srep10857

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biased random walk model for the prioritization of drug resistance associated proteinsPMID 26039373Read ↗

Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance.Semantic proximity Read ↗

Large-scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell LinesSemantic proximity Read ↗

<b>PANOPLY:</b> Omics-guided drug prioritization method tailored to an individual patientSemantic proximity Read ↗

Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer.Semantic proximity Read ↗

Artificial intelligence in tumor drug resistance: Mechanisms and treatment prospectsSemantic proximity Read ↗

Laplacian normalization and random walk on heterogeneous networks for disease-gene prioritization.Semantic proximity Read ↗

DIA-based Proteomics Identifies IDH2 as a Targetable Regulator of Acquired Drug Resistance in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Personalized characterization of diseases using sample-specific networks.Semantic proximity Read ↗

Emerging artificial intelligence-driven precision therapies in tumor drug resistance: recent advances, opportunities, and challengesSemantic proximity Read ↗

Signature reversion of three disease-associated gene signatures prioritizes cancer drug repurposing candidatesSemantic proximity Read ↗

GPEC: a Cytoscape plug-in for random walk-based gene prioritization and biomedical evidence collection.Semantic proximity Read ↗

Identification of disease treatment mechanisms through the multiscale interactomeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.